| Literature DB >> 35903580 |
Moza Alishaq1, Hanaa Nafady-Hego2, Andrew Jeremijenko3, Jameela Ali Al Ajmi4, Mohamed Elgendy5, Naser Ali Asad Al Ansari4, Hamed Elgendy4,6, Abdul-Badi Abou-Samra1,3, Adeel A Butt4,7,8.
Abstract
Objective: To determine the prevalence of SARS-CoV-2 virus infection among female workers who were restricted to working from home compared with those who continued to attend in-person work.Entities:
Keywords: COVID-19; Qatar; SARS-CoV-2; infections; women; work-place restrictions
Year: 2022 PMID: 35903580 PMCID: PMC9315056 DOI: 10.2147/IDR.S360241
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
Figure 1Study flowsheet.
Baseline Characteristics of Working Women with Work Restrictions (Restricted Group) vs Working Women with No Work Restrictions (Unrestricted Group)
| Restricted Group | Unrestricted Group | ||
|---|---|---|---|
| N=1636 | N=1190 | ||
| Median age (IQR) years | 37 (32, 44) | 30 (26, 35) | <0.0001 |
| Nationality, N (%) | <0.0001 | ||
| Indian | 814 (49.8) | 37 (3.1) | |
| Filipino | 228 (13.9) | 455 (38.2) | |
| Nepalese | 122 (7.5) | 353 (29.7) | |
| Sri Lankan | 136 (8.3) | 12 (1.0) | |
| Kenyan | 29 (1.8) | 167 (14.0) | |
| Egyptian | 57 (3.5) | 2 (0.2) | |
| British/Irish | 42 (2.6) | 1 (0.1) | |
| Tunisian | 8 (0.5) | 38 (3.2) | |
| Others | 200 (12.2) | 125 (10.5) | |
| Number of comorbidities | <0.0001 | ||
| None, N (%) | 1432 (87.5) | 1160 (97.5) | |
| 1–2, N (%) | 190 (11.6) | 30 (2.5) | |
| ≥3, N (%) | 14 (0.9) | 0 | |
| Comorbidities, N (%) | |||
| Diabetes | 42 (2.6) | 3 (0.3) | <0.0001 |
| Hypertension | 73 (4.5) | 8 (0.7) | <0.0001 |
| Cardiovascular disease | 9 (0.6) | 1 (0.1) | 0.04 |
| Chronic kidney disease | 3 (0.2) | 0 | 0.19 |
| Chronic lung disease | 46 (2.8) | 12 (1.0) | 0.001 |
| Chronic liver disease | 6 (0.4) | 0 | 0.04 |
| Cancer diagnosis | 3 (0.2) | 1 (0.1) | 0.44 |
| Immune disorders | 43 (2.6) | 1 (0.1) | <0.0001 |
| Symptomatic at baseline, N (%) | 287 (17.5) | 184 (15.5) | 0.14 |
| Contact with confirmed case, N (%) | 22 (1.3) | 68 (5.7) | <0.0001 |
| Accommodation status, N (%) | <0.0001 | ||
| Single housing | 21 (1.3) | 3 (0.3) | |
| Family housing | 1552 (94.9) | 45 (3.8) | |
| Shared with non-family members | 63 (3.9) | 1142 (96.0) | |
| Median Education (IQR) years | 16 (16, 16) | 16 (12, 16) | 0.23 |
| Seropositive, N (%) | 84 (5.1) | 270 (22.7) | <0.0001 |
| RT-PCR positive, N (%) | 55 (3.4) | 173 (14.7) | <0.0001 |
| Either/both positive, N (%) | 109 (6.7) | 286 (24.0) | <0.0001 |
Baseline Characteristics of Restricted and Unrestricted Staff with Any Evidence of SARS-CoV-2 Virus
| RT-PCR-SARS-CoV-2 Positivity | Anti-SARS-CoV-2 Positivity | |||||
|---|---|---|---|---|---|---|
| Restricted Group | Unrestricted Group | Restricted Group | Unrestricted Group | |||
| N (%) | 55 (3.4) | 173 (14.7) | <0.0001 | 84 (5.1) | 270 (22.7) | <0.0001 |
| Missing N, (%) | 10 | 29 | 0 | 0 | ||
| Seropositive, N (%) | 30 (54.5) | 157 (90.8) | <0.0001 | |||
| RT-PCR positive, N (%) | 30 (35.7) | 157 (59.2) | <0.0001 | |||
| Nationality, N (%) | <0.0001 | <0.0001 | ||||
| Indian | 13 (23.6) | 4 (2.3) | 40 (47.6) | 6 (2.2) | ||
| Filipino | 9 (16.4) | 53 (30.6) | 10 (11.9) | 88 (32.6) | ||
| Nepalese | 11 (20.0) | 83 (48.0) | 4 (4.8) | 111 (41.1) | ||
| Sri Lankan | 4 (7.3) | 1 (0.6) | 8 (9.5) | 1 (0.4) | ||
| Kenyan | 1 (1.8) | 20 (11.6) | 1 (1.2) | 35 (13.0) | ||
| Egyptian | 5 (9.1) | 0 | 6 (7.1) | 0 | ||
| British/Irish | 1 (1.8) | 0 | 2 (2.4) | 0 | ||
| Tunisian | 0 | 4 (2.3) | 0 | 6 (2.2) | ||
| Others | 11 (20.0) | 8 (4.6) | 13 (15.5) | 23 (8.5) | ||
| Number of Comorbidities, N (%) | <0.0001 | <0.0001 | ||||
| None | 41 (74.5) | 166 (96.0) | 69 (82.1) | 261 (96.7) | ||
| 1–2 | 13 (23.6) | 7 (4.0) | 14 (16.7) | 9 (3.3) | ||
| ≥3 | 1 (1.8) | 0 | 1 (1.2) | 0 | ||
| Comorbidities, N (%) | ||||||
| Diabetes | 4 (7.3) | 1 (0.6) | 0.003 | 5 (6.0) | 0 | <0.0001 |
| Hypertension | 3 (5.5) | 3 (1.7) | 0.13 | 5 (6.0) | 3 (1.1) | 0.009 |
| Cardiovascular disease | 0 | 1 (0.6) | 0.57 | 0 | 1 (0.4) | 0.58 |
| Chronic lung disease | 1 (1.8) | 3 (1.7) | 0.97 | 3 (3.6) | 4 (1.5) | 0.23 |
| Chronic liver disease | 1 (1.8) | 0 | 0.08 | 0 | 0 | |
| Neurological disease | 1 (1.8) | 0 | 0.08 | 1 (1.2) | 0 | 0.07 |
| Cancer diagnosis | 2 (3.6) | 0 | 0.01 | 1 (1.2) | 0 | 0.07 |
| Immune disorders | 1 (1.8) | 0 | 0.08 | 1 (1.2) | 0 | 0.07 |
| Rheumatological disease | 0 | 0 | 1 (1.2) | 0 | 0.07 | |
| Symptomatic at baseline, N (%) | 20 (36.4) | 81 (46.8) | 0.17 | 26 (31.0) | 89 (33.0) | 0.73 |
| Contact with confirmed case, N (%) | 10 (18.2) | 31 (17.9) | 0.97 | 10 (11.9) | 32 (76.2) | 0.99 |
| Accommodation status, N (%) | <0.0001 | <0.0001 | ||||
| Single housing | 0 | 0 | 0 | 1 (0.4) | ||
| Family housing | 55 (100.0) | 3 (1.7) | 1 (1.2) | 265 (98.1) | ||
| Shared with non-family members | 0 | 170 (98.3) | 83 (98.8) | 4 (1.5) | ||
| Median age (IQR) years | 36 (30, 40) | 30 (26, 35) | <0.0001 | 35.5 (31, 43) | 29 (26, 34.3) | <0.0001 |
| Median Education (IQR) years | 16 (16, 16) | 14 (10, 16) | 0.40 | 16 (16, 16) | 14 (11.5, 16) | 0.39 |
| Median CT value (IQR) | 24 (19, 32) | 25 (20, 31) | 0.65 | 22 (18, 30) | 25 (20, 31) | 0.36 |
| Median anti SARSCov-2 antibody (IQR) | 51.6 (18.6, 118.0) | 58.9 (22.0, 110.0) | 0.95 | 46.7 (14, 92.6) | 48.1(15.4, 94.4) | 0.84 |
| Need for hospitalization, N (%) | 3 (5.5) | 2 (1.2) | 0.06 | 2 (2.4) | 3 (1.1) | 0.39 |
| Pneumonia, N (%) | 2 (3.6) | 1 (0.6) | 0.08 | 1 (1.2) | 1 (0.4) | 0.38 |
Factors Associated with SARS-CoV-2 Infection Among Female Workers
| RT-PCR-SARS-CoV-2 Positivity | Anti-SARS-CoV-2 Positivity | |||
|---|---|---|---|---|
| Odds Ratio (95% CI) | Odds Ratio (95% CI) | |||
| Age 10-year increase | 0.84 (0.67–1.06) | 0.14 | 0.81 (0.68–0.97) | 0.03 |
| Nationality (vs Indian) | ||||
| Filipino | 2.41 (1.26–4.59) | 0.008 | 0.94 (0.59–1.50) | 0.81 |
| Nepalese | 7.47 (3.92–14.22) | <0.0001 | 1.78 (1.11–2.85) | 0.02 |
| Sri Lankan | 1.44 (0.51–4.08) | 0.50 | 0.91 (0.43–1.95) | 0.81 |
| Kenyan | 2.68 (1.22–5.90) | 0.01 | 0.99 (0.56–1.76) | 0.98 |
| Egyptian | 6.34 (2.15–18.72) | 0.001 | 2.03 (0.79–5.22) | 0.14 |
| British/Irish | 1.06 (0.13–8.71) | 0.96 | 0.92 (0.21–4.0) | 0.91 |
| Tunisian | 1.03 (0.29–3.73) | 0.96 | 0.46 (1.66–1.26) | 0.13 |
| Others | 1.40 (0.67–2.93) | 0.37 | 0.84 (0.50–1.42) | 0.53 |
| Symptomatic at baseline | 4.81 (3.30–7.0) | <0.0001 | 2.88 (2.09–3.97) | <0.0001 |
| Contact with confirmed case | 3.72 (2.10–6.56) | <0.0001 | 2.34 (1.37–3.98) | 0.002 |
| Unrestricted group (vs restricted) | 2.90 (1.86–4.51) | <0.0001 | 4.71 (3.24–6.86) | <0.0001 |
| Comorbidities (vs none) | ||||
| 1–2 | 1.97 (1.12, 3.47) | 0.02 | 1.37 (0.83–2.25) | 0.22 |
| ≥3 | 3.93 (0.46–33.6) | 0.21 | 1.99 (0.25–15.93) | 0.52 |